"Chelating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
| Descriptor ID |
D002614
|
| MeSH Number(s) |
D27.505.519.914.500 D27.720.832.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chelating Agents".
Below are MeSH descriptors whose meaning is more specific than "Chelating Agents".
This graph shows the total number of publications written about "Chelating Agents" by people in this website by year, and whether "Chelating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 3 | 4 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 2 | 3 |
| 2004 | 0 | 4 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 4 | 0 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chelating Agents" by people in Profiles.
-
Monovalent metal ion binding promotes the first transesterification reaction in the spliceosome. Nat Commun. 2023 Dec 20; 14(1):8482.
-
Head-to-head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti-FZD10 antibody OTSA101. Cancer Sci. 2023 Dec; 114(12):4677-4690.
-
High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders. Am J Nephrol. 2023; 54(5-6):219-223.
-
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472.
-
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
-
Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1041-1043.
-
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
-
Zinc deficiency induces hypertension by promoting renal Na+ reabsorption. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F646-F653.
-
Wilson's Disease: A Review for the General Pediatrician. Pediatr Ann. 2018 Nov 01; 47(11):e440-e444.
-
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.